ABSTRACT An empirical approach to treating Pneumocystis carinii pneumonia was adopted in a prospective study of 73 men with antibodies to human immunodeficiency virus 1 (HIV-1) presenting with respiratory problems. At presentation 49 patients (group 1) were thought to have a history, findings at clinical examination, chest radiograph, and arterial blood gas tensions typical of pneumocystis pneumonia, and empirical treatment was begun immediately. Twenty four patients (group 2) were thought to have features not typical of pneumocystis pneumonia. All patients were subsequently referred for bronchoscopy to determine the diagnosis. In group 1 four patients were excluded from the analysis because bronchoscopy was not possible. Of the remaining 45, 42 had pneumocystis pneumonia, which was diagnosed at bronchoscopy in 40, and on the basis of the clinical response to co-trimoxazole in two who had negative results from investigations. Of the three patients without pneumocystis pneumonia, one patient with lymphoid interstitial pneumonitis and Branhamella catarrhalis infection would have failed to respond to empirical treatment. The other two had multiple bacterial pathogens at bronchoscopy; one already had Kaposi's sarcoma and the other would have been misdiagnosed as having AIDS. In group 2 a specific diagnosis was made at bronchoscopy in 21 cases, including pneumocystis pneumonia in seven (all had atypical chest radiographs). In three cases no diagnosis was made and spontaneous recovery occurred. Adopting an empirical approach to treatment for typical pneumocystis pneumonia (group 1) led to the correct treatment in 43 of 45 cases (95%) and would have saved 44 of the 45 of bronchoscopies in this group. Adopting an empirical approach would have caused one patient to be misdiagnosed as having AIDS. Overall, 44 out of69 bronchoscopies (64%) would have been saved; the specificity for the diagnosis of pneumocystis pneumonia was 85% and the sensitivity was 85%. Adopting an "empirical" treatment policy for typical pneumocystis pneumonia will cause a large reduction in the number of "high risk" bronchoscopies performed.
Introduction
It has been advocated that all patients with suspected Pneumocystis carinii pneumonia who have antibodies to human immunodeficiency virus 1 (HIV-1) or who are from a "high risk" group should undergo fibreoptic bronchoscopy and bronchoalveolar lavage, with or without transbronchial biopsy, for a definitive diagnosis before treatment is begun.'`3 Whether this policy is a realistic one is questionable. In logistic terms, bronchoscopy for every HIV-I antibody positive patient presenting with respiratory symptoms and signs may soon be impossible. By December 1988 a total of 1982 cases of AIDS had been reported in the United Kingdom.4 Published data would suggest that over 60% of all patients with AIDS will have a respiratory illness (and some will have repeated episodes) during progression of the disease.56 The large and increasing numbers of patients requiring investigation of respiratory problems will place very heavy demands on clinicians, nursing staff, and in particular the laboratory services. The use of induced sputum to make a diagnosis will certainly reduce the numbers needing bronchoscopy but will not completely eliminate the need for this procedure. 559 560 We have previously reported our experience with 13 patients with a presumed diagnosis of pneumocystis pneumonia who were treated empirically without bronchoscopy.' In that study we proposed: (a) that patients with a history, findings at physical examination, chest radiograph, and arterial blood gas Miller, Millar, Weller, Semple history was taken, the patient was examined, a chest radiograph was obtained, and an arterial blood gas sample was obtained with the patient breathing room air. On the basis ofthe history, results ofexamination, chest radiograph, and blood gas analysis the patients were immediately assigned to one of two groups, depending on whether the findings were regarded as typical of pneumocystis pneumonia (group 1) or not (group 2). The criteria used in the allocation of patients to the two groups are listed in table 1. An empirical approach to treatment was adopted in group 1, who were immediately treated with "high dose" intravenous co-trimozazole. The patients in group 2 had one or more features of their history, findings at physical examination, chest radiograph, or blood gas tensions that were not usually seen in pneumocystis pneumonia and the presentation was considered atypical. These patients underwent bronchoscopy for a definite diagnosis.
Once treatment had been started in patients in group 1, we proceeded to perform bronchoscopies to obtain a laboratory based diagnosis for each patient, so that the validity of the "empirical" treatment policy could be tested.
Bronchoscopy was carried out with the patient sitting semi-upright and the bronchoscope was passed via the nose. Intravenous atropine 06 mg and metoclopramide 10 mg were given at the start of the procedure and topical lignocaine was applied to the nose and pyriform fossae (10% solution), to the vocal cords (4%), and below the cords (2%). During the procedure intravenous midazolam (2 5-7 5 mg) with or without alfentanil (0-25-05 mg) was used for sedation. Bronchoalveolar lavage was performed, with 180 ml of warmed buffered saline in 60 ml aliquots, and transbronchial biopsy specimens were obtained, without fluoroscopic control, from the Six patients had P carinii alone and another had P carinii and M tuberculosis. The radiological features that made the presentation of these patients atypical for pneumocystis pneumonia are listed in table 2. In 14 patients other diagnoses were made (fig 3) . In three patients no specific diagnosis was made. One patient, who was having treatment for cerebral toxoplasmosis with sulphadiazine and pyrimethamine and who also had cutaneous Kaposi's sarcoma, presented with a rapid onset of high fever and cough and right middle lobe consolidation on his chest radiograph (confirmed by computed tomography). At bronchoscopy no endobronchial lesion was seen, biopsy and lavage specimens from the middle lobe were negative, and the consolidation cleared rapidly without treatment. A second patient, with a four week history of fever and Miller, Millar, Weller, Semple used.'2 The risk of complications, particularly haemorrhage and pneumothorax, is particularly high when transbronchial biopsy is performed in patients whose lungs are infected with P carinii.'2 At the time of this study we routinely carried out both lavage and transbronchial biopsy, but now no longer perform transbronchial biopsy because of the risk ofcomplications and the low yield of additional diagnoses it produces. ' The use of induced sputum is a useful initial step in experienced laboratories in the evaluation of HIV-1 antibody positive patients with respiratory symptoms;'4 it should eventually help to reduce the number of bronchoscopic investigations performed, but it will not completely remove the need. Its diagnostic accuracy is up to 79%.'4 Bronchoscopy will still be necessary in those with negative results from induced sputum examination and in those whose clinical diagnosis and response to treatment are at variance with the microbiological or cytological diagnosis obtained from induced sputum. At the time of this study induced sputum examination was not routinely available in our hospital and bronchoscopy was the usual investigation.
Pneumocystis pneumonia is the mode of presentation in over half of all cases of AIDS,615 and it is responsible for up to 85% of all cases ofpneumonia in AIDS.516 In this study the typical presenting features of pneumocystis pneumonia (group 1, table 1) included a dry cough, which might have been of short or long duration,'7 18 and often a sensation of difficulty in taking in a deep breath.7 Pyrexia was almost invariable but patients rarely complained of fever. '9 On examination the chest may be entirely normal or fine basal crackles may be heard. Signs of consolidation suggest bacterial infection and pleural effusion tuberculosis,'9 and these features would be atypical (group 2, The policy adopted in this study has been criticised27 because (1) a definite pathogen could not be identified; (2) AIDS related pneumonia may be caused by a wide range ofpathogens, frequently with a second pathogen5; (3) a therapeutic response to high dose co-trimoxazole does not preclude the possibility of an infection with bacteria sensitive to cotrimoxazole; (4) identification of P carinii (or other opportunist organisms) establishes the diagnosis of AIDS,28 and permits discussion of the disease and prognosis with the patient, which is not possible if the diagnosis is "high dose co-trimoxazole responsive pneumonia."
Since then it has become apparent that second pathogens are not seen as frequently as previously reported (PC Hopewell, personal communication) and in particular the role of cytomegalovirus as a pathogen in AIDS related pneumonia has been questioned. 29 Multiple bacterial isolates are often encountered in both induced sputum and lavage fluid but their role as pathogens is doubtful. The technique of protected catheter acquisition of samples at fibreoptic bronchoscopy and their quantitative microbiological analysis gives reliable information where multiple organisms are seen in routine cultures of induced sputum or lavage fluid,'3' but these techniques are not widely used.
An empirical approach raises important ethical issues: in particular, can an HIV-1 antibody positive patient be confidently told that he or she has pneumocystis pneumonia on clinical grounds without bronchoscopy? This and other issues, however, have now largely been resolved with the revision of the case definition criteria for AIDS,32 as a clinical diagnosis of pneumocystis pneumonia with response to antipneumocystis treatment in an HIV-l antibody positive patient is sufficient to make a diagnosis of AIDS and places the patient in CDC category IV c. 32 In addition, in recent months it has become apparent that a substantial proportion ifnot all of the HIV-I antibody positive patients will ultimately develop AIDS. 33 In our patients who presented with features typical of pneumocystis pneumonia (group 1) two patients had negative results in investigations but responded rapidly to treatment and were thought to have pneumocystis pneumonia. One of the three remaining patients, who had lymphoid interstitial pneumonitis and B catarrhalis, would not have improved by day 5 of treatment and would have had bronchoscopy at that stage. An empirical approach would have been detrimental in the two other cases as they would have received inappropriately high doses of antibiotics with the associated risks of toxicity, and as they responded to high dose intravenous co-trimoxazole would have been misdiagnosed as having AIDS 
